Amgen, Teva Settle Patent Suit Over Neopogen Generic
By Jonathan Randles ( July 15, 2011, 10:04 PM EDT) -- A Pennsylvania federal judge on Friday approved a settlement between generics maker Teva Pharmaceuticals USA Inc. and Amgen Inc. that squashes Teva's hopes of marketing a copycat version of the blood drug Neopogen until 2013....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.